|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
The Scientist Magazine Recognizes Febit, Inc.'s HybSelect(TM) Among the Winners of "Top 10 Innovations of 2009"
12/2/2009 2:03:19 PM
LEXINGTON, Mass. and HEIDELBERG, Germany, December 2, 2009 – febit’s HybSelect has been recognized as one of the winners of the “Top 10 Innovations of 2009” by The Scientist magazine. The company’s automated sequence capture technology for high-throughput sequencing was selected due to its exceptional combinations of invention, vision and utility.
The Scientist gathered a panel of expert judges to evaluate a broad range of life science technologies and determined the best innovations to hit the life sciences market in 2009. The winners’ list includes a variety of products that capture both intracellular and extracellular processes. HybSelect is a robust and automated method for selecting and enriching high-value target regions from the genome that enables cost-effective massively parallel sequencing.
“Next-Generation Sequencing (NGS) is an accurate and high-performance technology for diagnostics and has been limited by throughput, cost, data management and automation issues,” said Peer Staehler, chief scientific officer of febit. “Instead of analyzing large-sequence stretches of a single genome, researchers using HybSelect are now able to focus on targeted re-sequencing of interesting regions from many different patients in parallel.”
HybSelect combines the advantages of microarray-based enrichment with patent protected microfluidic biochip technology and runs on the dedicated, highly automated instrument, the Geniom® RT Analyzer. It allows to conduct large scale clinical studies to identify SNPs and mutations as new biomarkers to receive statistically relevant data.
To read the full article of The Scientist please visit http://www.the-scientist.com/2009/12/1/41/1
About febit
febit develops, produces and markets flexible automated solutions for enabling biochip applications in Life Sciences. febit’s product portfolio includes various instruments, optimized assays and bioanalytical services, complemented by bioinformatics software and consulting.
The key applications are HybSelect, febit’s innovative DNA capture method for Next-Generation-Sequencing, and hands-off, amplification free microRNA profiling. Both are taking advantage of the advanced microfluidics of the patented Geniom Biochip to offer the highest degree of automation, flexibility and efficiency available.
For more information, please visit www.febit.com.
|
|
|
|
|
|
|
|
|
|
|